bluebird bio, Inc.
BCMA chimeric antigen receptors
Last updated:
Abstract:
The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.
Status:
Grant
Type:
Utility
Filling date:
23 Oct 2020
Issue date:
1 Jun 2021